Intracellular Free Cash Flow Operating Cash Flow Ratio from 2010 to 2024

ITCI Stock  USD 85.45  0.19  0.22%   
Intracellular's Free Cash Flow Operating Cash Flow Ratio is increasing with slightly volatile movements from year to year. Free Cash Flow Operating Cash Flow Ratio is estimated to finish at 1.10 this year. For the period between 2010 and 2024, Intracellular, Free Cash Flow Operating Cash Flow Ratio quarterly trend regression had mean deviation of  0.01 and range of 0.0995. View All Fundamentals
 
Free Cash Flow Operating Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
1.00216588
Current Value
1.1
Quarterly Volatility
0.02517497
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Intracellular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intracellular's main balance sheet or income statement drivers, such as Interest Expense of 8.9 M, Total Revenue of 487.6 M or Gross Profit of 452.2 M, as well as many indicators such as Price To Sales Ratio of 14.05, Dividend Yield of 0.0 or PTB Ratio of 7.67. Intracellular financial statements analysis is a perfect complement when working with Intracellular Valuation or Volatility modules.
  
Check out the analysis of Intracellular Correlation against competitors.

Currently Active Assets on Macroaxis

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:
Check out the analysis of Intracellular Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.87)
Revenue Per Share
6.096
Quarterly Revenue Growth
0.39
Return On Assets
(0.07)
Return On Equity
(0.1)
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.